Publications by authors named "H Gunen"
Introduction: Respiratory syncytial virus (RSV) is a common, highly contagious pathogen and a leading cause of serious illness among infants and older adults. While existing scientific evidence has predominantly focused on the epidemiology and disease burden of RSV in infants, data in older adults remain limited in some countries, including those in Southeast Asia (SEA) and the Middle East and North Africa (MENA) region. Here, we outline the key challenges for understanding the burden of RSV in older adults in SEA and the MENA region and we propose opportunities for improving understanding and eventually reducing the impact of RSV.
View Article and Find Full Text PDFObjective: Coronavirus disease 2019 is an ongoing disease with high morbidity and mortality. We aimed to investigate the relationship between demographics, lymphocytes, eosinophils, and the coronavirus disease 2019 severity at hospital admission.
Material And Methods: A retrospective, observational cross-sectional study was carried out with 5828 coronavirus disease 2019 patients between March 11, 2020, and November 30, 2020.
Article Synopsis
- - The study investigates the frequency of rare SERPINA1 mutations to improve management strategies for alpha1 antitrypsin deficiency (AATD), based on a secondary analysis of a large sample of 30,827 individuals across six countries.
- - Researchers utilized the Progenika A1AT Genotyping Test, discovering that 2.6% of cases had rare alleles, with the majority being heterozygous and a few homozygous; however, some expected mutations were not detected in the tested samples.
- - The findings reveal new insights into the distribution of rare alleles and suggest the need for more comprehensive testing and research to understand their pathogenic effects in different populations.
Purpose: GOLD 2019 proposed a novel treatment decision tool for follow-up based on the predominant trait (exacerbation or dyspnea) of patients, alongside treatment escalation and de-escalation strategies. This study was designed to provide an up-to-date snapshot of patient and disease characteristics, treatment pathways, and healthcare resource use (HRU) in COPD in real life, and comprehensively examine patients considering GOLD 2019 recommendations.
Patients And Methods: This mixed design, observational, multicenter (14 pulmonology clinics) study included all patients with a documented COPD diagnosis (excluding asthma-COPD overlap [ACO]) for ≥12 months, aged ≥40 years at diagnosis who had a COPD-related hospital visit, spirometry test and blood eosinophil count (BEC) measurement under stable conditions within the 12 months before enrollment between February and December 2020.